As Affymetrix Tries to Salvage Deal, eBioscience Explores Other Options | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Affymetrix said this week that it has released eBioscience from certain obligations under the terms of their proposed merger as the Santa Clara, Calif.-based array firm continues in its efforts to salvage the $330 million deal.

The company also disclosed a deal with a firm named Cellular Research, founded by Stephen Fodor, who also founded Affy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.